PoNS device cost
The PoNS® device costs $28,270 at list price in the United States, or $24,029.50 with the manufacturer's cash-pay discount, and the device is only one part of the cost of a 14-week PoNS Therapy® program. This page explains what the price consists of, what insurance and veterans' programs cover, and what a course of the same technology — translingual neurostimulation — costs when it is delivered outside the U.S. device market.
What the PoNS® price includes
| Item | List price | Cash-pay price (15% rebate) |
|---|---|---|
| PoNS® Controller | $19,580 | $16,643.00 |
| PoNS® Mouthpiece (single-patient) | $8,690 | $7,386.50 |
| Device total | $28,270 | $24,029.50 |
Figures are taken from the manufacturer's FAQ (ponstherapy.com) as of September 2026. The device is prescription-only and is cleared in the U.S. for gait deficit in mild-to-moderate multiple sclerosis (adults 22 and over) and, since 2026, for chronic gait deficit after stroke. On top of the device, a PoNS Therapy® program includes physiotherapy sessions in an authorised clinic during the first weeks and supervised home use for the rest of the 14-week course; these services are billed by the clinic and vary by provider.
Insurance, Medicare and the VA
Coverage in the United States has been expanding but is not universal. The manufacturer reports agreements with some commercial insurers, a Medicare payment determination for the controller and mouthpiece, and, since 2024, inclusion of the device on the Veterans Affairs Federal Supply Schedule, where the PoNS system is priced at $26,228.09 for veterans' facilities. Whether a particular patient is covered depends on the plan, the indication (MS or stroke) and the clinic; the manufacturer also runs a patient access program with financing. Patients outside the United States and Canada cannot buy the device at all: it is not sold there.
What TLNS costs outside the U.S. device market
PoNS® is one commercial device for translingual neurostimulation (TLNS), a method created at the University of Wisconsin–Madison. RehaLine's TLNS system is a separate device from the same scientific school, registered in Russia, Mexico, Uzbekistan and New Zealand. Because it is produced and registered outside the U.S. pricing system and delivered through our own and partner clinics, a full course — device, supervised phase and remote follow-up — costs several times less than the PoNS® device alone. The exact price depends on the country, the indication and the program format (clinic course, home program, or a medical-travel package for patients from countries without a local partner). We do not publish a single price because it differs by country and by what is included; request a quote and you will receive the full cost for your case, with nothing added later.
Two structural differences matter more than the headline number. First, the device stays with the patient after the course, so repeat cycles — the usual situation in cerebral palsy, Parkinson's disease and chronic brain injury — do not require buying or renting it again. Second, the program covers indications for which PoNS® is not cleared at all, including cerebral palsy in children from two years of age. See the full TLNS vs PoNS comparison.
Is the technology worth it?
The evidence for TLNS is strongest in chronic balance and gait deficits after mild-to-moderate traumatic brain injury (two randomized trials, 44 and 122 patients, about two-thirds of participants achieving a clinically meaningful improvement that was maintained 12 weeks after treatment) and in spastic cerebral palsy in children (a controlled study of 134 patients, motor function improving nearly three times faster than with standard rehabilitation). In multiple sclerosis the picture is mixed: positive pilot trials and a 2026 sham-controlled trial that found no added benefit at the dose used. A patient deciding whether to spend money on either device should start from the evidence for their own condition; our publications page lists all 54 studies with links, and our specialists will tell you frankly whether TLNS is indicated in your case.
Frequently asked questions
Does the $28,270 include physiotherapy?
No. It is the price of the device (controller and mouthpiece). Clinic sessions during the PoNS Therapy® program are billed separately by the treating clinic.
Can I rent a PoNS® device or buy a used one?
The device is prescription-only and the mouthpiece is single-patient; the manufacturer distributes it through authorised clinics. We do not sell, rent or service PoNS® devices.
How much does a RehaLine TLNS course cost?
Several times less than the PoNS® device; the exact amount depends on the country and program. Write to info@4stim.com or use the Telegram assistant with a short description of the case, and you will receive a quote for the full course.
Can a patient from the United States get a RehaLine TLNS course?
Not in the United States — the device is not FDA-cleared and is not offered for sale there. Patients from the USA can take a course in a RehaLine clinic or a partner clinic in a country where the device is registered.
PoNS® and PoNS Therapy® are trademarks of their respective owner. 4STIM and RehaLine Group are not affiliated with Bioness Medical, Helius Medical Technologies or their partners; product names are used only to identify the product discussed. Prices quoted for PoNS® are public figures from the manufacturer and may change without notice. The RehaLine TLNS device is not cleared by the U.S. FDA and is not offered for sale in the United States.